Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 12, 2019

THERAPEUTIC SOLUTONS INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada

000-54554

45-1226465

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

4093 Oceanside Boulevard, Suite B

Oceanside, California 92056

(Address of Principal Executive Offices and Zip Code)

(760) 295-7208

(Issuer's telephone number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On November 8, 2019 Mr. Timothy G. Dixon, the company CEO, entered into global settlement on monies owed to Mr. Dixon in the form of accrued payroll and a convertible note thereon totaling $534,714.68. Per the Agreement, Company will pay Mr. Dixon 0.5% of Net Sales (after COGS) of NanoStilbene *only* on a rolling 90 days to be paid out within 30 days of the close of previous 90-day period. Principal sum is frozen, and no further interest will be accrued. Missed payments are covered by an additional 30-day grace period and only that portion will accrue interest at a rate of 5% per annum. There are no other remedies other than stock conversion if a payment is missed. The promissory note is terminated.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

No.		Description
99.1		Mr. Dixon’s executed Agreement dated November 8, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 12, 2019

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.